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AdultBackground: Quadrivalent meningococcal conjugate vaccines (MenACWY) were developed to offer
long-term protection against invasive disease caused by serogroups A, C, W, and Y. Reduced
MenACWY effectiveness within 5 years after primary vaccination (likely due to declining bactericidal
antibody titers) has been described, particularly with respect to C and Y disease in the United States.
We evaluated the safety and immunogenicity of a single booster dose of quadrivalent meningococcal
polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D) in adolescents and adults who
received a previous dose 4–6 years earlier.
Methods: This phase 2, open-label, multicenter study of 834 persons was conducted in the United States.
Participants received a single 0.5-mL booster dose of MenACWY-D. Serogroup-specific bactericidal
antibody geometric mean titers (GMTs) were measured with a serum bactericidal antibody assay using
human complement (hSBA). Proportions of participants achieving antibody titers of P1:8 for each
vaccine serogroup on Days 6 and 28 were determined. Rates of adverse events (AEs), including serious
adverse events (SAEs), were also assessed.
Results: Before booster vaccination, 38.7–68.5% of participants had an hSBA titerP1:8, depending on vac-
cine serogroup. By Day 6 post-vaccination, 98.2–99.1% of participants had hSBA titers P1:8. By Day 28,
>99% of participants achieved this threshold and the primary hypothesis (lower limit of the one-sided
95% confidence limit P85% for each serogroup) was met. The GMT ratios (post-vaccination divided by
pre-vaccination) at Day 28 ranged from 47.2 (serogroup A) to 209.1 (serogroup Y). Rates of AEs, including
SAEs, were similar to those observed among adolescents and adults who received a primary dose of
MenACWY-D in previous studies. There were no study discontinuations due to an AE and no deaths.
Conclusions: Booster vaccination with MenACWY-D was safe and induced robust bactericidal antibody
responses, consistent with immune memory, among adolescents and adults 4–6 years after primary
vaccination.
ClinicalTrials.gov registration: NCT01442675.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
The aerobic gram-negative diplococcus Neisseria meningitidis is
a leading cause of bacterial meningitis, with the most commonpresentation of invasive meningococcal disease (IMD) being puru-
lent meningitis [1]. Meningococcal sepsis without meningitis
occurs in 5–20% of cases of IMD [1]. The overall case-fatality ratio
for meningococcal disease is 10–15%, while meningococcal sepsis
is fatal in 40% of cases [1]. Up to 10% of adolescents and adults
are transient asymptomatic carriers of meningococci, and trans-
mission is primarily through the exchange of nasopharyngeal
secretions from colonized or infected individuals [1]. Although at
least 12 meningococcal serogroups have been identified on the
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five (A, B, C, W, and Y) have been primarily responsible for IMD
worldwide, while a sixth serogroup (X) has emerged since 2006
as an important cause of IMD in Africa [1–4].
Prior to the introduction of the serogroup A meningococcal
polysaccharide-tetanus toxoid conjugate vaccine in sub-Saharan
Africa in 2010, an estimated 1.2 million new cases of IMD occurred
globally each year in both endemic and epidemic forms, resulting
in approximately 135,000 deaths [5]. In the United States, provi-
sional surveillance estimates for 2014 indicate a total of 450 cases
of meningococcal disease (0.14 cases per 100,000 population),
resulting in an estimated 65 deaths (0.02 deaths per 100,000 pop-
ulation) [6]. Incidence of meningococcal disease in the United
States varies according to age, with infants younger than one year
of age being at the greatest risk, followed by persons 16 through
21 years of age [7,8]. The financial burden imposed by IMD on
the healthcare system in the United States is substantial, as docu-
mented by a population-based observational study that reported
the cost per hospitalization due to meningococcal meningitis as
having risen from $18,417 in 1997 to $55,251 in 2010 [9]. The
public health impact and economic burden of meningococcal
infection underscore the need for effective vaccines and their opti-
mal use.
Two quadrivalent (ACWY) conjugate vaccines (one conjugated
to diphtheria toxoid and the other to a non-toxic mutant of diph-
theria toxin [CRM197]), one quadrivalent (ACWY) polysaccharide
vaccine, one bivalent (CY) conjugate vaccine, and two serogroup
B vaccines are currently available for use in the United States for
active immunization against meningococcal disease in various
age groups [7,10]. Conjugate vaccines are effective across a wide
age range, including children younger than 2 years of age, and offer
an advantage over unconjugated polysaccharide vaccines in that
they elicit T-cell–dependent responses characterized by the
generation of memory B cells that drive booster antibody
responses to exposure or to subsequent doses of conjugate vaccine
[11]. Moreover, unlike unconjugated vaccines, they do not induce
immunologic hyporesponsiveness, a phenomenon marked by an
attenuated antibody response to subsequent antigenic exposure
that results from the depletion of the memory B-cell pool [11]. A
recent comparison of the population structure of invasive
N. meningitidis in the United States before (2000–2005) and after
(2006–2010) the introduction of conjugate vaccines has revealed
substantial differences in the serogroup distribution between the
two periods; however, vaccine-driven serogroup replacement
was not evident [12].
Quadrivalent meningococcal polysaccharide diphtheria toxoid
conjugate vaccine (MenACWY-D), which is currently registered in
more than 50 countries, was first licensed in the United States in
2005 for active immunization against IMD in adolescents and
adults 11 through 55 years of age, in 2007 for use in children
two through 10 years of age, and in 2011 for use in infants and tod-
dlers nine through 23 months of age [7]. Although protective levels
of antibodies have been documented up to three years following
primary vaccination of adolescents with MenACWY-D [13], dimin-
ished vaccine effectiveness against C and Y disease in the United
States has been described. This has been attributed to declining
serum bactericidal assay (SBA) antibody titers over time, which
have been observed in children first vaccinated at 2 years of age
and in adolescents [7,13–17]. In 2010, the Advisory Committee
on Immunization Practices (ACIP) in the United States recom-
mended that a booster dose of MenACWY be administered at age
16 years if the primary dose had been administered at age 11 or
12 years, or at age 16 through 18 years if the primary dose had
been administered at age 13 through 15 years [18]. In light of these
recommendations, we conducted study MTA77, a phase 2, open-
label study to determine the safety and immunogenicity of a singlebooster dose of MenACWY-D in persons who had received their
first dose 4–6 years previously.2. Methods
2.1. Study design
This phase 2, open-label study was conducted between Septem-
ber 2011 and July 2012 at 15 centers in the United States and eval-
uated the safety and immunogenicity of a single booster dose of
MenACWY-D 4–6 years after prior vaccination in persons first vac-
cinated at P11 years of age. The study was conducted in compli-
ance with the Edinburgh revision of the Declaration of Helsinki
[19] and followed International Committee on Harmonisation
(ICH) guidelines for Good Clinical Practice (GCP) [20]. Written
informed consent was provided by participants or their parent(s)
or legal guardian(s) before enrollment. The study is registered at
ClinicalTrials.gov (NCT01442675).
2.2. Participants
Participants were <56 years of age and had received
MenACWY-D within 4–6 years prior to study enrollment, at age
P11 years. Exclusion criteria included a history of documented
IMD, receipt of any meningococcal vaccine other than a single dose
of MenACWY-D 4–6 years prior to enrollment, receipt of any vac-
cine within 30 days before receiving study vaccine (except for
influenza vaccine, which could be administered up to 15 days
before study vaccine), chronic illness that could interfere with
study conduct or completion, history of Guillain-Barré syndrome,
potential contraindications for intramuscular (IM) administration
(thrombocytopenia, bleeding disorder, or receipt of anticoagulants
in the 3 weeks preceding vaccination), or receipt of antibiotic(s)
within 72 h prior to the first blood draw. Temporary exclusion
criteria included moderate or severe acute illness, infection, or
febrile illness (temperature P38.0 C); enrollment of prospective
participants with these conditions was delayed until the condition
was resolved.
2.3. Study vaccine and administration
Each 0.5-mL single-dose vial of MenACWY-D (Menactra vac-
cine, Sanofi Pasteur, Swiftwater, Pennsylvania, USA; batch number:
U3845AA) contained 4 lg of capsular polysaccharide from each of
the four serogroups covalently attached to a total of approximately
48 lg of diphtheria toxoid protein and was formulated in sterile,
pyrogen- and preservative-free phosphate-buffered physiological
saline. The vaccine was administered on Day 0 as a single 0.5-mL
IM injection in the deltoid region, using a needle of appropriate
length (at the discretion of the investigator) to ensure IM delivery.
2.4. Immunogenicity objectives and endpoints
The primary immunogenicity objective was to evaluate anti-
body responses to the four serogroups (A, C, W, and Y), measured
by serum bactericidal assay using human complement (hSBA),
which was performed as previously described [21]. The hSBA
determines the concentration of group-specific functional antibod-
ies against meningococci, and titers P1:4 have been directly
correlated to protection against meningococcal disease [22,23].
The endpoint for this objective was the proportion of participants
achieving hSBA antibody titers P1:8 to the four serogroups in
serum specimens collected 28 (window, 21–35) days post-
vaccination. The secondary immunogenicity objective was to eval-
uate antibody (memory) responses by hSBA to the four serogroups
Table 1
Participant demographics.
Demographic characteristics N = 834
Gender: n (%)
Male 400 (48.0)
Female 434 (52.0)
Age: (years)
Mean 17.8
Median 17.1
Standard deviation 3.2
Range 15.0–53.7
Racial origin: n (%)
Asian 8 (1.0)
African American 49 (5.9)
White 751 (90.0)
American Indian or Alaska Native 2 (0.2)
Native Hawaiian or other Pacific Islander 2 (0.2)
Other 22 (2.6)
Ethnic origin: n (%)
Hispanic or Latino 28 (3.4)
Not Hispanic or Latino 806 (96.6)
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vaccination in a subset of 120 participants. The endpoint for this
objective was the proportion of participants achieving hSBA anti-
body titers P1:8 to the four serogroups.
2.5. Safety objectives and endpoints
The safety objective was to describe the rates of immediate
adverse events (AEs), solicited injection-site and systemic reac-
tions, unsolicited nonserious AEs, and serious adverse events
(SAEs) following vaccination. Safety endpoints included the occur-
rence, time to onset, duration, and intensity of: immediate AEs
occurring within 20 min after vaccination; solicited injection-site
and systemic reactions occurring up to 7 days after vaccination;
unsolicited nonserious AEs occurring between Day 0 and Day 28;
and any SAE occurring within 6 months post-vaccination. Relation-
ship to vaccination was assessed for unsolicited systemic AEs that
occurred within 20 min of vaccination, unsolicited nonserious AEs
occurring between Day 0 and Day 28, and SAEs; AEs involving the
injection-site were presumed to be related to vaccination. AEs con-
sidered related to vaccination were termed adverse reactions
(ARs). Adverse events were defined using preferred terms from
the Medical Dictionary for Regulatory Activities (MedDRA) version
14.0.
2.6. Serologic evaluations
The hSBA was performed in the sponsor’s laboratory according
to established procedures that have been previously described
[21]. The lower limit of quantitation of the hSBA was a titer of 1:4.
2.7. Statistical methods and determination of sample size
All statistical analyses were performed using SAS software
(Version 9.1 or later; SAS Institute, Inc., Cary, North Carolina, USA).
Continuous demographic variables are presented by summary
statistics (eg, mean and standard deviation [SD], minimum, and
maximum) and categorical variables are presented by frequency
distributions (eg, frequency counts, percentages, and their 95%
confidence intervals [CIs] calculated using the exact method).
The hypothesis for the primary endpoint was that the propor-
tion of participants achieving an hSBA antibody titerP1:8 follow-
ing a booster dose of MenACWY-D vaccine would be P85% for
each serogroup. The hypothesis was considered to be supported
if the lower one-sided 95% confidence limit (CL) for the observed
proportion was P85%, calculated using the exact binomial
(Clopper-Pearson) method, quoted by Newcombe (ie, using the
inverse of the beta integral with SAS) [24]. A sample size of 750
evaluable participants was estimated to provide at least 95% power
to achieve the primary hypothesis for each serogroup, assuming
the true response was >90%, and assuming independent immune
responses to each serogroup among and within participants. In
addition, with 834 participants enrolled, there was a probability
of approximately 95% to observe at least one AE, given a true inci-
dence as low as 0.4%. No imputation for missing data was per-
formed. For the secondary endpoint—the proportion of persons
with hSBA titers P1:8 and P1:4 in the subset of 120 participants
evaluated 6 (window, 5–7) days following vaccination—95% CIs of
point estimates were calculated assuming proportions follow a
binomial distribution, using the exact method.
Calculation of geometric mean titers (GMTs) assumed that the
Log2 transformation of the titers/data followed a normal
distribution. The mean and the 95% CI were first calculated on
Log2 (titers/data) using the usual calculation for the normal distri-
bution (Student’s t distribution with n-1 degree of freedom), thenantilog transformations were applied to the results of calculations
in order to provide geometric means and their 95% CIs.
Immunogenicity analyses were conducted using the per-
protocol analysis set (PPAS), which comprised participants who
received the dose of study vaccine and complied with all
protocol-specified requirements and procedures. The full analysis
set (FAS) (ie, the intent-to-treat population) consisted of all partic-
ipants who received a dose of study vaccine and had a post-
vaccination serology result. Safety analyses were conducted using
the safety analysis set, which comprised all participants who
received the study vaccine and for whom safety data were
available.
3. Results
3.1. Demographic characteristics and disposition of participants
A total of 834 participants enrolled and 822 (98.6%) completed
the study. Most participants were white (90.0%), 52% were female,
and the mean (SD) age was 17.8 (3.2) years (Table 1). Reasons for
discontinuing the study included noncompliance (n = 6 [0.7%]),
loss to follow-up (n = 2 [0.2%]), and voluntary withdrawal of con-
sent (n = 4 [0.5%]) (Table 2). Of 834 enrolled participants, 831 were
included in the safety analysis set, 820 were included in the FAS,
and 781 were included in the PPAS (Table 2).
3.2. Immunogenicity evaluations
The results from the PPAS are presented; the FAS produced sim-
ilar results (data not shown).
Prior to booster vaccination, the percentages of participants
with an hSBA titer P1:8 were 64.5%, 44.2%, 68.5%, and 38.7% for
serogroups A, C, W, and Y, respectively. More than 98% of partici-
pants had hSBA antibody titers P1:8 for all serogroups by Day 6
post-vaccination and >99% achieved this threshold by Day 28
(Table 3). At Day 28, the lower limit of the one-sided 95% CL was
P85% for serogroups A, C, W, and Y, meeting the primary
hypothesis-specified proportion. Geometric mean titers for all
antigens increased substantially postvaccination (Table 4). The
geometric mean ratios of post-vaccination:pre-vaccination titers
at 28 days postvaccination ranged from 47.2 (serogroup A) to
209.1 (serogroup Y).
In additional analyses of the primary immunogenicity endpoint,
there were no material differences by age (15–18 years vs.
Table 2
Disposition of participants.
N = 834
n (%)
Participants completing study 822 (98.6)
Participants discontinued 12 (1.4)
Reason for discontinuation
Noncompliance with protocol 6 (0.7)
Lost to follow-up 2 (0.2)
Voluntary withdrawal of consent 4 (0.5)
Participants in the safety analysis seta 831 (99.6)
Participants in the full analysis set (FAS)b 820 (98.3)
Participants in the Day 28 per-protocol analysis set (PPAS) 781 (93.6)
Participants in the FAS but not included in the PPAS 39 (4.7)
Reason for exclusion
Did not satisfy inclusion/exclusion criteria 7 (0.8)
Blood not drawn within protocol-specified time windows 13 (1.6)
Pre-vaccination serology sample did not produce valid
test result
1 (0.1)
Other protocol violation likely to affect immune response
or immunogenicity assessment
18 (2.2)
a Three enrolled participants were not included the safety analysis set because
they were not vaccinated.
b Eleven enrolled participants were not included in the FAS because they did not
provide a post-vaccination blood sample.
Table 3
Participants with hSBA antibody titers P1:8 dilution at Days 0, 6 and 28 post-vaccination
N = 781
n/M % (95% CI)
Serogroup A
Day 0 504/781 64.5 (61.1; 67.9)
Day 6 110/112 98.2 (93.7, 99.8)
Day 28 776/781 99.4 (98.5, 99.8)
Serogroup C
Day 0 345/781 44.2 (40.7; 47.7)
Day 6 111/112 99.1 (95.1, 100)
Day 28 778/781 99.6 (98.9, 99.9)
Serogroup W
Day 0 535/781 68.5 (65.1; 71.7)
Day 6 111/112 99.1 (95.1, 100)
Day 28 780/781 99.9 (99.3, 100)
Serogroup Y
Day 0 302/781 38.7 (35.2; 42.2)
Day 6 111/112 99.1 (95.1, 100)
Day 28 779/781 99.7 (99.1, 100)
n, number of participants with hSBA titer P1:8 dilution; M, number of participants wit
a The primary hypothesis tested was that the lower limit of the one-sided 95% CL wa
Table 4
Geometric mean hSBA antibody titers (per-protocol analysis set).
N = 781
M GMT (95%
Serogroup A
Prevaccination 781 8.9 (8.3, 9
Day 6 112 227.6 (166
Day 28 781 421.2 (378
Serogroup C
Prevaccination 781 8.8 (7.8, 1
Day 6 112 639.8 (457
Day 28 781 1135.0 (10
Serogroup W
Prevaccination 781 13.8 (12.4
Day 6 112 702.0 (508
Day 28 781 1271.6 (11
Serogroup Y
Prevaccination 781 6.2 (5.6, 6
Day 6 112 655.8 (474
Day 28 781 1303.6 (11
M, number of participants with data available; GMT, geometric mean titer; CI, confiden
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shown).3.3. Safety evaluations
Solicited reactions were reported by 76.4% of participants
(Table 5). Most began within 3 days post-vaccination, resolved
within 1–3 days, and were grade 1 or grade 2 in intensity. The most
common solicited injection-site reaction was pain, which occurred
in 60.2% of participants. The most common solicited systemic
reactions were myalgia (42.8%), followed by headache (38.6%)
and malaise (29.4%).
One immediate AE of grade 1 dizziness occurred in one
participant within 20 min of vaccination. Unsolicited AEs were
reported in 245 (29.5%) participants (Table 6). The most
commonly reported unsolicited AEs were nasopharyngitis and
headache (each reported in 24 [2.9%] of participants). Most
unsolicited AEs were grade 1 or 2 in intensity. Unsolicited ARs
were reported in 14 (1.7%) of participants. ARs reported in more
than 1 participant included injection-site hematoma (n = 3;
0.4%), injection-site pruritus (n = 3; 0.4%), and vomiting (n = 2;
0.2%).(per-protocol analysis set).
Lower limit of one-sided 95% CL Hypothesis Test Successa
98.7 Yes
99.0 Yes
99.4 Yes
99.2 Yes
h available data; CI, confidence interval; CL, confidence limit.
s P85%.
CI) GM (95% CI) of
Post-vaccination: Pre-vaccination Ratio
.6)
.4, 311.3) 30.5 (21.8, 42.5)
.8, 468.3) 47.2 (42.3, 52.7)
0.0)
.4, 895.0) 64.0 (42.7, 95.9)
13.0, 1271.8) 128.3 (112.0, 147.0)
, 15.3)
.0, 970.2) 45.5 (31.0, 67.0)
45.3, 1411.8) 92.4 (81.1, 105.4)
.9)
.8, 905.9) 121.1 (84.5, 173.5)
83.1, 1436.4) 209.1 (184.4, 237.1)
ce interval; GM, geometric mean.
Table 5
Solicited reactions (safety analysis set).
N = 831
Participants experiencing at least one: n/M % (95% CI)
Solicited reaction 628/822 76.4 (73.3, 79.3)
Solicited injection-site reaction 497/821 60.5 (57.1, 63.9)
Pain 494/821 60.2 (56.7, 63.5)
Grade 2 121/821 14.7 (12.4, 17.4)
Grade 3 20/821 2.4 (1.5, 3.7)
Erythema 10/821 1.2 (0.6, 2.2)
Grade 2 1/821 0.1 (0.0, 0.7)
Grade 3 0/821 0 (0.0, 0.4)
Swelling 14/281 1.7 (0.9, 2.8)
Grade 2 3/821 0.4 (0.1, 1.1)
Grade 3 0/821 0 (0.0, 0.4)
Solicited systemic reaction 509/822 61.9 (58.5, 65.3)
Fever 6/817 0.7 (0.3, 1.6)
Grade 2 1/817 0.1 (0.0, 0.7)
Grade 3 0/817 0 (0.0, 0.5)
Headache 317/822 38.6 (35.2, 42.0)
Grade 2 113/822 13.7 (11.5, 16.3)
Grade 3 22/822 2.7 (1.7, 4.0)
Malaise 242/822 29.4 (26.3, 32.7)
Grade 2 64/822 7.8 (6.0, 9.8)
Grade 3 23/822 2.8 (1.8, 4.2)
Myalgia 352/822 42.8 (39.4, 46.3)
Grade 2 87/822 10.6 (8.6, 12.9)
Grade 3 19/822 2.3 (1.4, 3.6)
Shivering 102/822 12.4 (10.2, 14.9)
Grade 2 24/822 2.9 (1.9, 4.3)
Grade 3 6/822 0.7 (0.3, 1.6)
n, number of participants with event; M, number of participants with available
data; CI, confidence interval.
Injection-site pain, headache, malaise, myalgia and shivering: grade 2 for some
interference with activity and grade 3 for significant interference or prevention of
daily activity.
Injection-site erythema and injection-site swelling: grade 2 for reactions measuring
P51 to 6100 mm and grade 3 for reactions measuring >100 mm.
Fever: grade 2 for temperature P39.0 C to 639.9 C and grade 3 for temperature
P40.0 C.
Table 6
Unsolicited AEs and ARs (safety analysis set).
N = 831
Participants experiencing at least one: n % (95% CI)
AEs 245 29.5 (26.4, 32.7)
Immediate AE 1 0.1 (0.0, 0.7)
Nonserious AE 224 29.4 (26.3, 32.6)
Grade 3 38 4.6 (3.3, 6.2)
Nonserious systemic AE 237 28.5 (25.5, 31.7)
Grade 3 38 4.6 (3.3, 6.2)
ARs 14 1.7 (0.9, 2.8)
Immediate AR 0 0 (0.0, 0.4)
Nonserious AR 14 1.7 (0.9, 2.8)
Grade 3 1 0.1 (0.0, 0.7)
Nonserious injection-site AR 8 1.0 (0.4, 1.9)
Grade 3 0 0 (0.0, 0.4)
Nonserious systemic AR 6 0.7 (0.3, 1.6)
Grade 3 1 0.1 (0.0, 0.7)
n, number of participants with event; AE, adverse event; AR, adverse reaction; CI,
confidence interval.
Grade 3 for significant interference or prevention of daily activity.
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6-month follow-up period. Two SAEs of bronchitis and suicidal
ideation occurred during the first 28 days of the study; both partic-
ipants recovered without sequelae. All SAEs were considered to be
unrelated to vaccination. No deaths occurred during the study.
There were no material differences in the frequencies of soli-
cited AEs, unsolicited nonserious AEs, or SAEs by age (15–18 yearsvs. P19 years), race (white vs. non-white), or gender (data not
shown).4. Discussion
This study demonstrated the safety and immunogenicity of
booster vaccination with MenACWY-D among adolescents and
adults 4–6 years after prior vaccination. Robust bactericidal
responses were observed for all vaccine serogroups. As early as
Day 6, >98% of trial participants achieved hSBA titersP1:8, consis-
tent with an anamnestic response. By Day 28, >99% of participants
had hSBA titers P1:8. As further evidence of the robust memory
response associated with booster vaccination with MenACWY-D,
GMTs increased up to 100-fold within 6 days post-vaccination
and up to 200-fold within 28 days.
Moreover, booster vaccination 4–6 years after the primary dose
revealed no apparent safety concerns. Overall, rates of solicited
reactions were comparable to those seen among adolescents and
adults who received a primary dose of MenACWY-D in previous
studies [25]. Rates of SAEs were low and none were considered
vaccine-related.
The findings of this study are consistent with the findings of two
previous studies assessing MenACWY-D booster vaccination. Key-
serling and colleagues also observed that MenACWY-D safely
induced robust booster responses in healthy adolescents who were
primed 3 years beforehand [13]. Unpublished study MTA62
(NCT00700713) demonstrated that MenACWY-D was also safe
and induced robust booster responses in a younger cohort, children
4–5 years of age who had received one or two doses 3 years earlier
as infants and toddlers [26]. Of note, the serogroup-specific GMTs
observed after booster vaccination in the current study population
(median age: 17.1 years) were approximately 3- to 10-fold lower
than those observed in the Keyserling et al. study population
(median age: 17.0 years at time of booster vaccination). However,
the Keyserling et al. study used an SBA with baby rabbit sera as
the complement source, which generally results in higher SBA titers
compared to the hSBA, the assay that was used in the current study
[27]. This underscores the notion that comparison of SBA titers
across different studies should generally be avoided since such com-
parisons are only valid when serum specimens from the same study
population are assayed together, using a single complement source.
Although an earlier study of MenACWY-D in adolescents had
demonstrated the persistence of bactericidal activity up to 3 years
following initial vaccination [13], waning of antibody levels over
time has been documented [14–17]. Findings from the current
study also suggest waning antibody levels after primary
MenACWY-D vaccination, given the relatively low GMTs that were
observed immediately prior to booster vaccination. Of note, GMTs
and the proportion of participants with hSBA titers P1:8 before
vaccination were lower or trended lower for serogroups C and Y
compared to serogroups A and W. In contrast, other studies either
demonstrated greater or a trend toward greater antibody persis-
tence following MenACWY-D for serogroups C and Y compared
to serogroup A or W [13,28]. These serogroup-specific differences
in antibody persistence within the same study may be related to
differences in natural exposure to cross-reacting polysaccharide
antigens since antibody decay usually follows a predictable slope
in the absence of other modifying events.
Waning immunity after primary vaccination notwithstanding,
the current study demonstrated that a subsequent dose of
MenACWY-D was effective in inducing a robust booster response
for all vaccine serogroups. The observed antibody responses sup-
port current recommendations of the ACIP that in the US a booster
dose be administered to all persons aged 16–18 years if the primary
dose was administered before the sixteenth birthday [7]. The evi-
5278 C.A. Robertson et al. / Vaccine 34 (2016) 5273–5278dence of primary protection as demonstrated in earlier studies of
infants and toddlers [21] and adolescents [13] and the finding of
robust booster responses at least 3–6 years after priming suggest
that substantial public health benefitsmay accrue from the primary
and booster use of MenACWY-D. In fact, between introduction of
the vaccine and 2012–2013, there had been an 80% reduction in
the incidence of serogroup C, Y, and W disease among U.S. adoles-
cents, the population that is the target of the U.S. immunization
program [8]. As a conjugate vaccine, MenACWY-D offers substantial
benefits, including the potential for reducing nasopharyngeal car-
riage of meningococci [29], the induction of immunologic memory,
and the ability to avoid immunological hyporesponsiveness [11].
The latter characteristic may particularly benefit those who require
repeated meningococcal vaccination, including immunocompro-
mised persons, elderly individuals, previously vaccinated travelers
returning to areas where IMD is endemic, and persons at
prolonged increased risk for IMD (eg, microbiologists working with
meningococcal isolates).
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